Conditions: Glioma; Diffuse Glioma; Recurrent Gliomas
Interventions: Drug: Oral Vorasidenib administered once daily for up to 12 treatment cycles (28 days per cycle) as IDH-targeted therapy in participants with recurrent or residual IDH-mutant diffuse glioma.
Sponsors: Huashan Hospital; SCU West China Lecheng Hospital
Not yet recruiting Conditions: Glioma; Diffuse Glioma; Recurrent Gliomas
Interventions: Drug: Oral Vorasidenib administered once daily for up to 12 treatment cycles (28 days per cycle) as IDH-targeted therapy in participants with recurrent or residual IDH-mutant diffuse glioma.
Sponsors: Huashan Hospital; SCU West China Lecheng Hospital
Not yet recruiting
